India, April 18 -- Histogen Inc. (HSTO), a drug development company for treatment of bacterial skin infections, said that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders.
Histogen noted that it plans to promptly propose and confirm a plan of liquidation and make distributions to the benefit of its estate.
The company announced on September 18, 2023, that it had discontinued further development and would seek approve for a Plan of Dissolution.
For comments and feedback contact: editorial@rttnews.com
Pub...